Joint EFGCP / DIA / EMA
Better Medicines for Children Conference 2014 on

Explore Ways to Enhance Collaboration Between Key Players

30th September & 1st October 2014
EMA Headquarters, London, United Kingdom

Organised by

EFGCP
where science and ethics meet

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

DIA
www.diahome.org



conferences@efgcp.eu – www.efgcp.eu

Conference Rationale

The EU paediatric regulation is now in force since 2007. Drug development is no longer possible without considering children. Furthermore, companies developing medicines need to consider the paediatric requirements early in the development. This legislation has transformed paediatric drug development from a topic discussed by a few interested paediatricians, clinical pharmacologists and regulators to an issue that is broadly known within pharmaceutical industry and regulatory authorities, and to a lesser degree in the clinical world. More than 1000 PIP decisions are now published on the EMA website, and virtually everybody within pharmaceutical industry has heard of paediatric investigation plans and waivers. The EU Commission has published a 5-year report, and a 10-year report will be submitted by the Commission to the European Parliament and Council in 2017.

The aim of this conference is to discuss on a high level how the EU paediatric regulation is working and how it contributes to children's health. This will include a discussion on the preparedness for the 10-year report; strategic thoughts within the EMA on how to streamline paediatric development and a session dedicated to paediatric oncology.

As always, experts from all involved parties will be present, and on day 1 participants will discuss more specialized and hot topic issues in four breakout sessions. This will allow participants to discuss face-to-face with all stakeholders, which otherwise usually occurs by email or phone. Questions on any topic relating to the Agency's activities can be submitted before the conference to paediatrics@efgcp.eu, and will be answered by Peter Karolyi from the Paediatric Medicines office at the EMA.

Programme Committee

Gesine Bejeuhr	vfa Research-based Pharmaceutical Companies, DIA Paediatric Group, Germany
Emilie Desfontaine	European Medicines Agency (EMA)
Thorsten Olski	European Medicines Agency (EMA)
Jytte Lyngvig	Drug Information Association (DIA), Switzerland
Klaus Rose	klausrose Consulting & EFGCP Children's Medicines Working Party, Switzerland
Paolo Tomasi	European Medicines Agency (EMA)
Mette Due Theilade Thomsen	Novo Nordisk, Denmark

Faculty

Peter Adamson	The Children's Hospital of Philadelphia, United States
Kate Beaujeux	MedImmune, United Kingdom
Gesine Bejeuhr	vfa Research-based Pharmaceutical Companies, DIA Paediatric Group, Germany
Gerlind Bode	International Confederation of Childhood Cancer Parent Organizations (ICCCPO), Germany
Christina Bucci-Rechtweg	Novartis Pharmaceuticals, Switzerland
Alexander Cvetkovich-Muntañola	INC Research, Spain
Emilie Desfontaine	European Medicines Agency (EMA)
Irmgard Eichler	European Medicines Agency (EMA)
Oliver Gross	University Medicine Göttingen, Germany
Ralf Herold	European Medicines Agency (EMA)
Peter Karolyi	European Medicines Agency (EMA)
Dirk Mentzer	Paediatric Committee (PDCO), European Medicines Agency (EMA) & Paul Ehrlich Institut, Germany
Koenraad Norga	Paediatric Committee (PDCO), European Medicines Agency (EMA) & Antwerp University Hospital (UZA), Belgium
Thorsten Olski	European Medicines Agency (EMA)

Andy Pearson	Institute of Cancer Research, United Kingdom
Solange Rohou	AstraZeneca, United Kingdom
Klaus Rose	klausrose Consulting & EFGCP Children's Medicines Working Party, Switzerland
Agnes Saint-Raymond	European Medicines Agency (EMA)
Mette Due Theilade Thomsen	Novo Nordisk, Denmark
Paolo Tomasi	European Medicines Agency (EMA)
Gilles Vassal	Gustave Roussy, France
Philip Walson	Georg-August-University Medical School, Göttingen, Germany

Conference Language

The language of the conference will be English.

Conference Venue

EMA Headquarters (NEW ADDRESS!)
Churchill Place 30, Canary Wharf
London E14 5AB, United Kingdom
Website: www.ema.europa.eu

Registration & Information

E-mail conferences@efgcp.eu or visit www.efgcp.eu

Programme

Tuesday 30th September

08:00 Registration & Welcome Coffee

08:45 Welcome

***Emilie Desfontaine**, European Medicines Agency (EMA) & **Klaus Rose**, klausrose Consulting & EFGCP Children's Medicines Working Party, Switzerland*

SESSION 1
SETTING THE SCENE

Chairperson: ***Emilie Desfontaine**, European Medicines Agency (EMA)*

09:00 Preparedness for the 10-year report and perspectives of the PDCO chairman
***Dirk Mentzer**, Chairman of the Paediatric Committee (PDCO), European Medicines Agency (EMA) & Paul Ehrlich Institut, Germany*

09:30 The Drug Developers' Perspective
***Christina Bucci-Rechtweg**, Novartis Pharmaceuticals, Switzerland*

10:00 Discussion

10:30 Coffee Break

11:00 Parallel break-out groups

Group 1 Pre-competitive paediatric collaboration between pharma companies and the role of EnprEMA?
Chair: ***Gesine Bejeuhr**, vfa Research-based Pharmaceutical Companies, DIA Paediatric Group, Germany*
Introduction: ***Irmgard Eichler**, European Medicines Agency (EMA)*

Group 2 Practical challenges of paediatrics clinical trials
Chair: ***Mette Due Theilade Thomsen**, Novo Nordisk, Denmark*
Introduction: ***Alexander Cvetkovich-Muntañola**, INC Research, Spain*

Group 3 Practical challenges with PIPs
Chair: ***Klaus Rose**, klausrose Consulting & EFGCP Children's Medicines Working Party, Switzerland*
Introduction: ***Kate Beaujeux**, MedImmune, United Kingdom*

Group 4 International framework for paediatric drug development
Chair: ***Emilie Desfontaine**, European Medicines Agency (EMA)*
Introduction: ***Agnes Saint-Raymond**, European Medicines Agency (EMA)*

13:00 Lunch

SESSION 2
GROUP REPORTS AND FEEDBACK FROM EMA

Chairpersons: *Mette Due Theilade Thomsen, Novo Nordisk, Denmark & Klaus Rose, klausrose Consulting & EFGCP Children's Medicines Working Party, Switzerland*

14:00 Feedback from the 4 parallel breakout groups
Rapporteurs of the Groups

15:00 One stop-shop: a new EMA approach
Paolo Tomasi, European Medicines Agency (EMA)

15:30 Report & Tentative answers on questions collected prior to the conference (send questions to paediatrics@efgcp.eu) / Update on paediatric procedures / PIP Format and content guideline revision
Peter Karolyi, European Medicines Agency (EMA)

16:00 Panel & General Discussion

16:50 Conclusions

17:00 End of Day 1

18:30 Social Event

- Key note speech: *Professor Philip Walson, Board Certified in Paediatrics, Clinical Pharmacology and Medical Toxicology; Visiting Professor, Department of Laboratory Medicine at Georg-August-University Medical School, Goettingen, Germany*

Wednesday 1st October

08:30 Welcome coffee

SESSION 3
ENHANCED COLLABORATION BETWEEN KEY PLAYERS

Chairpersons: *Ralf Herold, European Medicines Agency (EMA) & Gesine Bejeuhr, vfa Research-based Pharmaceutical Companies, DIA Paediatric Group, Germany*

09:00 Paediatric Oncology: The EU Perspective
Gilles Vassal, Gustave Roussy, France

09:25 Paediatric Oncology: The US Perpective
Peter Adamson, The Children's Hospital of Philadelphia, United States

09:50 Paediatric Oncology: The UK ICR Perspective
Andy Pearson, Institute of Cancer Research, United Kingdom

10:15 Paediatric Oncology: The Parent of Patient Perspective
Gerlind Bode, International Confederation of Childhood Cancer Parent Organizations (ICCCPO), Germany

10:40 Coffee Break

11:00 EMA / PDCO Representative
Koenraad Norga, Chairman of the Paediatric Committee (PDCO), European Medicines Agency (EMA) & Antwerp University Hospital (UZA), Belgium

11:35 Allport Syndrom: Challenges of clinical research and its translation into clinical practice
Oliver Gross, University Medicine Göttingen, Germany

12:00 Panel Discussion
Speakers of the session

13:00 Lunch

SESSION 4
INTERNATIONAL DEVELOPMENT IN PAEDIATRICS

Chairperson: *Thorsten Olski, European Medicines Agency (EMA)*

14:00 ICH E 11/ ICH E 6
Dirk Mentzer, Paediatric Committee (PDCO), European Medicines Agency (EMA) & Paul Ehrlich Institut, Germany

14:20 ICH E 11/ ICH E 6
Solange Rohou, AstraZeneca, United Kingdom

14:40 TTIP (Transatlantic Trade and Investment Partnership)
Speaker invited

15:00 Panel & General Discussion

15:50 Conference Wrap Up
Thorsten Olski, European Medicines Agency (EMA) & Mette Due Theilade Thomsen, Novo Nordisk, Denmark

16:00 End of Day 2